The Efficacy and Safety of Bevacizumab Plus Anti-PD-1/PD-L1 Inhibitors in Combination with Hepatic Arterial Infusion Chemotherapy for Initially Unresectable Hepatocellular Carcinoma

Overview

Journal Immunotargets Ther

Publisher Dove Medical Press

Specialty Allergy & Immunology

Date 2024 Oct 31

PMID 39478940

Authors

Xiang Tang

Jinbin Chen

Wei Peng

Zhoutian Yang

Li Hu

Zhiwei Ye

Yizhen Fu

Dandan Hu

Zhongguo Zhou

Minshan Chen

Yaojun Zhang

Jun-Cheng Wang

Affiliations

Soon will be listed here.

Abstract

Objection: To report the efficacy and safety of triple combination therapy with bevacizumab plus anti-PD-1 (BP1) or anti-PD-L1 inhibitors (BPL) combined with hepatic arterial infusion chemotherapy (HAIC) as a first-line treatment for initially unresectable hepatocellular carcinoma (uHCC).

Methods: In this retrospective study, patients with initially uHCC received either BP1-HAIC or BPL-HAIC as first-line treatment. The primary endpoint was progression-free survival (PFS); secondary endpoints included overall survival (OS), objective response rate (ORR) and disease control rate (DCR).

Results: Between January 2020 and December 2022, a total of 136 patients with initially uHCC received triple combination therapy, with 76 in the BP1-HAIC group and 60 in the BPL-HAIC group. The median PFS for the entire cohort was 11.1 months (95% CI, 8.0-13.7 months), and the median OS was 22.4 months (95% CI, 21.3- not reached). Comparative analysis revealed no significant differences in PFS (HR, 0.91, = 0.69) or OS (HR, 0.71, = 0.31) between the BP1-HAIC and BPL-HAIC groups. The ORR was 46.3% per RECIST v1.1 and 66.9% per mRECIST, with a DCR of 83.1% under both criteria. Common adverse events (AEs) included hypoalbuminemia and elevated aspartate/alanine aminotransferase, with 5.1% (7/136) experienced upper gastrointestinal bleeding. Multivariate Cox analysis identified tumor number and BCLC stage as independent prognostic factors for OS, and tumor number for PFS.

Conclusion: Triple combination therapy demonstrated significant therapeutic efficacy and tumor response in initially uHCC. No notable differences in outcomes were observed between the BP1-HAIC and BPL-HAIC groups. AEs were manageable in clinical practice.

References

He M, Liang R, Zhao Y, Xu Y, Chen H, Zhou Y . Lenvatinib, toripalimab, plus hepatic arterial infusion chemotherapy lenvatinib alone for advanced hepatocellular carcinoma. Ther Adv Med Oncol. 2021; 13:17588359211002720. PMC: 8010824. DOI: 10.1177/17588359211002720. View

Eisenhauer E, Therasse P, Bogaerts J, Schwartz L, Sargent D, Ford R . New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2008; 45(2):228-47. DOI: 10.1016/j.ejca.2008.10.026. View

Cheng A, Qin S, Ikeda M, Galle P, Ducreux M, Kim T . Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma. J Hepatol. 2021; 76(4):862-873. DOI: 10.1016/j.jhep.2021.11.030. View

Vogel A, Finn R, Blanchet Zumofen M, Heuser C, Alvarez J, Leibfried M . Atezolizumab in Combination with Bevacizumab for the Management of Patients with Hepatocellular Carcinoma in the First-Line Setting: Systematic Literature Review and Meta-Analysis. Liver Cancer. 2023; 12(6):510-520. PMC: 10697759. DOI: 10.1159/000533166. View

Forner A, Reig M, Bruix J . Hepatocellular carcinoma. Lancet. 2018; 391(10127):1301-1314. DOI: 10.1016/S0140-6736(18)30010-2. View

Kulik L, El-Serag H . Epidemiology and Management of Hepatocellular Carcinoma. Gastroenterology. 2018; 156(2):477-491.e1. PMC: 6340716. DOI: 10.1053/j.gastro.2018.08.065. View

Benson A, DAngelica M, Abbott D, Anaya D, Anders R, Are C . Hepatobiliary Cancers, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2021; 19(5):541-565. DOI: 10.6004/jnccn.2021.0022. View

Vogel A, Martinelli E . Updated treatment recommendations for hepatocellular carcinoma (HCC) from the ESMO Clinical Practice Guidelines. Ann Oncol. 2021; 32(6):801-805. DOI: 10.1016/j.annonc.2021.02.014. View

Zhang W, Zhang K, Liu C, Gao W, Si T, Zou Q . Hepatic arterial infusion chemotherapy combined with anti-PD-1/PD-L1 immunotherapy and molecularly targeted agents for advanced hepatocellular carcinoma: a real world study. Front Immunol. 2023; 14:1127349. PMC: 10169627. DOI: 10.3389/fimmu.2023.1127349. View

10.

Huang Q, Zheng Y, Gao Z, Yuan L, Sun Y, Chen H . Comparative Efficacy and Safety of PD-1/PD-L1 Inhibitors for Patients with Solid Tumors: A Systematic Review and Bayesian Network Meta-analysis. J Cancer. 2021; 12(4):1133-1143. PMC: 7797652. DOI: 10.7150/jca.49325. View

11.

Kim S, Cassella C, Byrne K . Tumor Burden and Immunotherapy: Impact on Immune Infiltration and Therapeutic Outcomes. Front Immunol. 2021; 11:629722. PMC: 7882695. DOI: 10.3389/fimmu.2020.629722. View

12.

Zhang T, Geng Z, Zuo M, Li J, Huang J, Huang Z . Camrelizumab (a PD-1 inhibitor) plus apatinib (an VEGFR-2 inhibitor) and hepatic artery infusion chemotherapy for hepatocellular carcinoma in Barcelona Clinic Liver Cancer stage C (TRIPLET): a phase II study. Signal Transduct Target Ther. 2023; 8(1):413. PMC: 10603153. DOI: 10.1038/s41392-023-01663-6. View

13.

Villanueva A . Hepatocellular Carcinoma. N Engl J Med. 2019; 380(15):1450-1462. DOI: 10.1056/NEJMra1713263. View

14.

Lyu N, Lin Y, Kong Y, Zhang Z, Liu L, Zheng L . FOXAI: a phase II trial evaluating the efficacy and safety of hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin for advanced hepatocellular carcinoma. Gut. 2017; 67(2):395-396. DOI: 10.1136/gutjnl-2017-314138. View

15.

Liu D, Mu H, Liu C, Zhang W, Cui Y, Wu Q . Sintilimab, bevacizumab biosimilar, and HAIC for unresectable hepatocellular carcinoma conversion therapy: a prospective, single-arm phase II trial. Neoplasma. 2024; 70(6):811-818. DOI: 10.4149/neo_2023_230806N413. View

16.

Qin B, Xin L, Liang C, Li L, Song Q, Long Y . Efficacy and safety of anti-PD-1 inhibitor versus anti-PD-L1 inhibitor in first-line treatment of extensive-stage small cell lung cancer: a multicenter retrospective study. BMC Cancer. 2024; 24(1):100. PMC: 10795417. DOI: 10.1186/s12885-024-11833-6. View

17.

Duan J, Cui L, Zhao X, Bai H, Cai S, Wang G . Use of Immunotherapy With Programmed Cell Death 1 vs Programmed Cell Death Ligand 1 Inhibitors in Patients With Cancer: A Systematic Review and Meta-analysis. JAMA Oncol. 2019; 6(3):375-384. PMC: 6990765. DOI: 10.1001/jamaoncol.2019.5367. View

18.

. Management consensus guideline for hepatocellular carcinoma: 2016 updated by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan. J Formos Med Assoc. 2017; 117(5):381-403. DOI: 10.1016/j.jfma.2017.09.007. View

19.

Lencioni R, Llovet J . Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010; 30(1):52-60. DOI: 10.1055/s-0030-1247132. View

20.

Zeng H, Xu Q, Wang J, Xu X, Luo J, Zhang L . The effect of anti-PD-1/PD-L1 antibodies combined with VEGF receptor tyrosine kinase inhibitors versus bevacizumab in unresectable hepatocellular carcinoma. Front Immunol. 2023; 14:1073133. PMC: 9900113. DOI: 10.3389/fimmu.2023.1073133. View